The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and a focus on advancing its allogeneic cell therapy platform
ZURICH and NESS ZIONA, Israel, Dec. 30, 2024 /PRNewswire/ — NLS Pharmaceutics Ltd. (“NLS”) (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, and Kadimastem Ltd. (“Kadimastem”) (TASE: KDST), a clinical-stage cell therapy company developing and manufacturing “off-the-shelf” allogeneic cell products for the treatment of neurodegenerative diseases and potential cure of diabetes, announced today that NLS has filed a Registration Statement on Form F-4 (“Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) regarding the previously announced merger between NLS and Kadimastem.
Financial Market Newsflash
No financial news published today. Check back later.
